JP2014530898A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530898A5 JP2014530898A5 JP2014537732A JP2014537732A JP2014530898A5 JP 2014530898 A5 JP2014530898 A5 JP 2014530898A5 JP 2014537732 A JP2014537732 A JP 2014537732A JP 2014537732 A JP2014537732 A JP 2014537732A JP 2014530898 A5 JP2014530898 A5 JP 2014530898A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- agent
- prostate cancer
- amino acid
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552796P | 2011-10-28 | 2011-10-28 | |
| US61/552,796 | 2011-10-28 | ||
| PCT/GB2012/052675 WO2013061083A2 (en) | 2011-10-28 | 2012-10-26 | Therapeutic agents and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530898A JP2014530898A (ja) | 2014-11-20 |
| JP2014530898A5 true JP2014530898A5 (https=) | 2015-12-10 |
| JP6101274B2 JP6101274B2 (ja) | 2017-03-22 |
Family
ID=47326213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537732A Active JP6101274B2 (ja) | 2011-10-28 | 2012-10-26 | 治療剤およびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9345782B2 (https=) |
| EP (1) | EP2771037B1 (https=) |
| JP (1) | JP6101274B2 (https=) |
| KR (2) | KR102232811B1 (https=) |
| CN (1) | CN104159618B (https=) |
| AU (1) | AU2012328173B2 (https=) |
| BR (1) | BR112014010739A2 (https=) |
| CA (1) | CA2853669C (https=) |
| DK (1) | DK2771037T3 (https=) |
| ES (1) | ES2601459T3 (https=) |
| IL (1) | IL232262A (https=) |
| LT (1) | LT2771037T (https=) |
| MX (1) | MX353964B (https=) |
| PL (1) | PL2771037T3 (https=) |
| PT (1) | PT2771037T (https=) |
| RU (1) | RU2606773C2 (https=) |
| WO (1) | WO2013061083A2 (https=) |
| ZA (1) | ZA201403372B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013061083A2 (en) | 2011-10-28 | 2013-05-02 | Fredax Ab | Therapeutic agents and uses thereof |
| MY193914A (en) | 2012-03-05 | 2022-11-01 | Oy Arctic Partners Ab | Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume |
| SMT201900338T1 (it) * | 2013-11-19 | 2019-07-11 | Fredax Ab | Anticopri anti-callicreina-2 umanizzato |
| GB2520353A (en) * | 2013-11-19 | 2015-05-20 | Fredax Ab | Antibody polypeptides and uses thereof |
| DK3123381T3 (da) | 2014-03-28 | 2023-11-27 | Opko Diagnostics Llc | Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer |
| US12326453B2 (en) | 2014-03-28 | 2025-06-10 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| EP3154587B1 (en) | 2014-06-13 | 2020-01-15 | Tenboron OY | Conjugates comprising an anti-egfr1 antibody |
| WO2016160545A1 (en) | 2015-03-27 | 2016-10-06 | Opko Diagnostics, Llc | Prostate antigen standards and uses thereof |
| CN108136013B (zh) * | 2015-10-05 | 2023-04-18 | 弗雷达克斯有限责任公司 | 抗体多肽及其用途 |
| EP4649966A3 (en) | 2016-12-01 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| US10183041B2 (en) * | 2017-04-12 | 2019-01-22 | Vector Vitale Ip Llc | Antibacterial composition and its use in treating bacterial infections |
| DE202017006951U1 (de) | 2017-08-14 | 2019-02-07 | Opko Diagnostics, Llc | Multiplex-Assays zur Beurteilung des Prostatakrebsstatus |
| JP7339692B2 (ja) * | 2019-03-29 | 2023-09-06 | 国立研究開発法人量子科学技術研究開発機構 | 放射性標識化合物の製造方法及び製造装置 |
| BR112022001368A2 (pt) | 2019-07-26 | 2022-05-24 | Janssen Biotech Inc | Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos |
| CN112294760B (zh) * | 2019-07-26 | 2025-12-12 | 宁波新致生物科技有限公司 | 一种液体制剂及其应用 |
| AU2020322221A1 (en) | 2019-07-26 | 2022-03-24 | Janssen Biotech, Inc. | Anti-hK2 chimeric antigen receptor (CAR) |
| CN112295112A (zh) * | 2019-07-31 | 2021-02-02 | 广州康近医疗技术有限公司 | 前列腺癌β粒子腔内治疗机 |
| CN116249714A (zh) | 2020-05-27 | 2023-06-09 | 詹森生物科技公司 | 包含cd3抗原结合结构域的蛋白质及其用途 |
| WO2025034663A2 (en) * | 2023-08-04 | 2025-02-13 | The General Hospital Corporation | Differentiation of patients with and without prostate cancer using urine 1h nmr metabolomics |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| US5807978A (en) | 1995-06-07 | 1998-09-15 | Kokolus; William J. | Immunogenic peptides of prostate specific antigen |
| US6379669B1 (en) * | 1995-08-04 | 2002-04-30 | Akhouri A. Sinha | Targeting of organs by immunoconjugates |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| CN1238013A (zh) | 1996-11-14 | 1999-12-08 | 梅奥医学教育及研究基金会 | 转移性前列腺癌的检测方法 |
| US7053042B1 (en) | 1999-07-29 | 2006-05-30 | Samuel Denmeade | Activation of peptide prodrugs by hK2 |
| WO2001012218A1 (en) | 1999-08-16 | 2001-02-22 | Zonagen, Inc. | Methods and materials for the treatment of prostatic carcinoma |
| FI20002127A0 (fi) * | 2000-09-27 | 2000-09-27 | Artic Partners Oy Ab | Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi |
| WO2002098897A2 (en) | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| US20040219163A1 (en) | 2001-10-03 | 2004-11-04 | Frelinger John G. | Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2 |
| EP2347767A3 (en) * | 2003-01-31 | 2013-06-12 | Albor Biologics, Inc. | Immune regulation based on the targeting of early activation molecules |
| US7492512B2 (en) | 2004-07-23 | 2009-02-17 | Mirage International Ltd. | Wide field-of-view binocular device, system and kit |
| US8663600B2 (en) * | 2005-02-17 | 2014-03-04 | Diaprost Ab | Diagnosis of prostate cancer |
| PE20071101A1 (es) * | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| KR100723009B1 (ko) | 2005-11-30 | 2007-05-29 | 한국원자력연구원 | 인간 ｐ３１ 유전자를 함유하는 악성 종양 치료용 약학적조성물 |
| CL2007002225A1 (es) * | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
| US8481683B2 (en) | 2006-12-01 | 2013-07-09 | Medarex, Inc. | Human antibodies that bind CD22 and uses thereof |
| WO2013061083A2 (en) | 2011-10-28 | 2013-05-02 | Fredax Ab | Therapeutic agents and uses thereof |
| SMT201900338T1 (it) | 2013-11-19 | 2019-07-11 | Fredax Ab | Anticopri anti-callicreina-2 umanizzato |
-
2012
- 2012-10-26 WO PCT/GB2012/052675 patent/WO2013061083A2/en not_active Ceased
- 2012-10-26 KR KR1020147014297A patent/KR102232811B1/ko active Active
- 2012-10-26 ES ES12798792.3T patent/ES2601459T3/es active Active
- 2012-10-26 EP EP12798792.3A patent/EP2771037B1/en active Active
- 2012-10-26 BR BR112014010739A patent/BR112014010739A2/pt not_active Application Discontinuation
- 2012-10-26 JP JP2014537732A patent/JP6101274B2/ja active Active
- 2012-10-26 MX MX2014005143A patent/MX353964B/es active IP Right Grant
- 2012-10-26 CN CN201280065063.4A patent/CN104159618B/zh active Active
- 2012-10-26 CA CA2853669A patent/CA2853669C/en active Active
- 2012-10-26 AU AU2012328173A patent/AU2012328173B2/en active Active
- 2012-10-26 US US14/354,617 patent/US9345782B2/en active Active
- 2012-10-26 PT PT127987923T patent/PT2771037T/pt unknown
- 2012-10-26 LT LTEP12798792.3T patent/LT2771037T/lt unknown
- 2012-10-26 DK DK12798792.3T patent/DK2771037T3/en active
- 2012-10-26 RU RU2014121499A patent/RU2606773C2/ru active
- 2012-10-26 KR KR1020217008459A patent/KR102362358B1/ko active Active
- 2012-10-26 PL PL12798792T patent/PL2771037T3/pl unknown
-
2014
- 2014-04-27 IL IL232262A patent/IL232262A/en active IP Right Grant
- 2014-05-12 ZA ZA2014/03372A patent/ZA201403372B/en unknown
-
2016
- 2016-04-21 US US15/135,028 patent/US20160317683A1/en not_active Abandoned
-
2019
- 2019-11-11 US US16/679,778 patent/US20200138986A1/en not_active Abandoned
-
2022
- 2022-01-07 US US17/570,933 patent/US12383637B2/en active Active
-
2025
- 2025-07-15 US US19/270,073 patent/US20260048159A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530898A5 (https=) | ||
| RU2014121499A (ru) | Терапевтические средства и их применение | |
| Omarini et al. | Pneumonitis and pulmonary fibrosis associated with breast cancer treatments | |
| Vanan et al. | DIPG in children–what can we learn from the past? | |
| Cheung et al. | Anti-G (D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. | |
| Bilynsky et al. | Radiation nanosensitizers in cancer therapy—From preclinical discoveries to the outcomes of early clinical trials | |
| RU2016124229A (ru) | Полипептиды антител и их применения | |
| JP2010017189A5 (https=) | ||
| Dietrich et al. | Improving external beam radiotherapy by combination with internal irradiation | |
| JP2016540503A5 (https=) | ||
| Chester et al. | Engineering antibodies for clinical applications in cancer | |
| Kim et al. | Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy | |
| van der Sar et al. | Tolerability of concurrent external beam radiotherapy and [177Lu] Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial) | |
| BR112019022308A2 (pt) | Método para o tratamento do câncer usando um inibidor bcl-2 junto com um radioimunoterapêutico emissor alfa | |
| Engel et al. | Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins | |
| Liu et al. | Lutetium Lu 177 vipivotide tetraxetan for prostate cancer | |
| Allen et al. | Quo vadis radiotherapy? Technological advances and the rising problems in cancer management | |
| Liu et al. | Autophagy inhibition improves the targeted radionuclide therapy efficacy of 131I-FAP-2286 in pancreatic cancer xenografts | |
| CN111905101B (zh) | 一种cd47抗体联合il-6细胞因子药在肿瘤治疗中的应用及验证其治疗肿瘤的方法 | |
| Fionda et al. | Abscopal effect and interventional oncology: state of art and future perspectives | |
| CN113853220A (zh) | 用于中枢神经系统肿瘤治疗的放射性微球 | |
| KR20230010656A (ko) | 금 나노 입자 함유 의약 | |
| Bal et al. | Radionuclide therapy for hepatocellular carcinoma: indication, cost and efficacy | |
| RU2018115734A (ru) | Полипептиды антител и их применение | |
| Khatua et al. | Recent advances in the treatment of childhood brain tumors |